Although most studies revealed that GAS6-AS1 functions as an oncogene and was highly expressed in gastric, hepatocellular, breast cancers and acute myeloid leukemia (AML), there were studies found that low GAS6-AS1 expression was associated with poor prognosis in lung cancer patients and that GAS6-AS1 overexpression inhibited lung adenocarcinoma progression [9–15]. This evidence concerns the gene GAS6 and breast carcinoma.